OBJECTIVE To follow the change in streptokinase neutralisation titres in a group of patients after treatment with streptokinase for acute myocardial infarction. DESIGN Venous blood samples suitable for analysis were obtained up to 866 days after treatment with 1.5 million units of streptokinase in 189 patients. The ability of the patient's plasma to inhibit lysis of a thrombin clot by strepto...

Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers a...

Methods are described by which thrombolytic therapy with local and systemic infusion of streptokinase can be initiated and controlled.

T HE FEASIBILITY of producing dissolution of thrombi by enzymatic means has been demonstrated in experimental thrombi and pulmonary emboli in animals, in experimental venous thrombi in man6 and in patients with acute venous and arterial thromboembolic disease.7 8 Of the enzymes investigated, only the two plasminogen activators, streptokinase and urokinase, have proved acceptable as thrombolytic...

Tinospora crispa, a plant belonging to the family of Menispermaceae is a well-known traditional medicinal plant used in Bangladesh. The methanolic extracts of stems of the plant were evaluated for their thrombolytic and preliminary cytotoxic activities. The thrombolytic activity was evaluated using the in vitro clot lysis model while while the screening of cytotoxic activity was done using brin...

We have determined the plasma level of fibrinopeptide A as a specific index of thrombin activity during the infusion of a thrombolytic agent in patients with acute myocardial infarction. Peripheral venous plasma levels of fibrinopeptide A increased following the initiation of thrombolytic therapy from 2.7 nmol/L to a peak of 13.0 nmol/L at 30 minutes with streptokinase and from 1.1 nmol/L to a ...

The aim of the study was to investigate the thrombolytic activity of Punica granatum and Azadirachta indica over canine, bovine, caprine and avian blood clot using streptokinase and water as positive and negative control respectively. Using an in vitro thrombolytic model, the clot lysis activity of A. indica was observed as 48.06±0.59%, 50.01±1%, 47.6±0.69% and 28.03±0.35% and of P. granatum as...

Vasculitis developed in six of 253 patients treated with intravenous anisoylated plasminogen streptokinase activator complex (APSAC) after acute myocardial infarction. All patients recovered spontaneously with no evidence of renal impairment and no long term sequelae. Although leucocytoclastic vasculitis and serum sickness have been reported after streptokinase treatment, such allergic reaction...

Streptokinase is an extracellular protein, extracted from certain strains of beta hemolytic streptococcus. It is a non-protease plasminogen activator that activates plasminogen to plasmin, the enzyme that degrades fibrin cloth through its specific lysine binding site; it is used therefore as a drug in thrombolytic therapy. The rate of bacterial growth and streptokinase production was studied in...

Objectives. This study sought to demonstrate the equivalence of saruplase and streptokinase in terms of 30-day mortality. Background. The use of thrombolytic agents in the treatment of acute myocardial infarction is well established and has been shown to substantially reduce post-myocardial infarction mortality. Methods. Three thousand eighty-nine patients with symptoms compatible with those of...